摘要
目的:观察升阳除湿防风汤联合化疗治疗晚期胃癌患者的临床疗效及血清糖类抗原72-4(CA72-4)、可溶性细胞间黏附分子-1(sICAM-1)变化。方法:选择86例晚期胃癌患者,根据治疗方法将其分为两组,各43例,化疗组给予常规化疗治疗,观察组在化疗组基础上给予升阳除湿防风汤治疗,比较两组客观缓解率(ORR)、疾病控制率(DCR)、中医症状积分、血清CA72-4、sICAM-1水平、T淋巴细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、不良反应总发生率。结果:观察组ORR、DCR均较化疗组更高(P<0.05)。观察组治疗后畏寒肢冷、脘腹胀满、恶心呕吐、神疲乏力积分均较化疗组更低(P<0.05)。观察组治疗后血清CA72-4、sICAM-1水平均较化疗组更低(P<0.05)。观察组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较化疗组更高(P<0.05),CD8^(+)较化疗组更低(P<0.05)。观察组血小板减少、贫血、脱发、恶心、呕吐总发生率与化疗组比较,差异无统计学意义(P>0.05)。结论:升阳除湿防风汤联合化疗可有效提高晚期胃癌客观缓解率、疾病控制率,缓解脘腹胀满等症状,改善免疫功能,纠正免疫失衡,降低血清CA72-4、sICAM-1表达量,且未增加不良反应发生率。
Objective:To analyze the clinical efficacy of Shengyang Chushi Fangfeng decoction combined with chemotherapy in the treatment of advanced gastric cancer and the changes of serum carbohydrate antigen 72-4(CA72-4)and soluble intercellular adhesion molecule-1(sICAM-1).Methods:A total of 86 patients with advanced gastric cancer were selected and divided into 2 groups with 43 cases in each group according to different treatment methods.The chemotherapy group was given conventional chemotherapy,and the observation group was given Shengyang Chushi Fangfeng decoction on the basis of chemotherapy.Objective response rate(ORR),disease control rate(DCR),TCM syndrome score,serum CA72-4,sICAM-1 levels,T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and total incidence of adverse reactions were compared between the two groups.Results:ORR and DCR in observation group were higher than those in chemotherapy group(P<0.05).After treatment,the scores of cold limbs,abdominal distension,nausea and vomiting and fatigue in observation group were lower than those in chemotherapy group(P<0.05).After treatment,the levels of serum CA72-4 and sICAM-1 in observation group were lower than those in chemotherapy group(P<0.05).After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)were higher in observation group than in chemotherapy group(P<0.05),and CD8^(+)was lower than chemotherapy group(P<0.05).The total incidence of thrombocytopenia,anemia,alopecia,nausea,vomiting in observation group was higher than that in chemotherapy group(P>0.05).Conclusion:Shengyang Chushi Fangfeng decoction combined with chemotherapy can effectively improve the objective remission rate and disease control rate of advanced gastric cancer,relieve symptoms such as epigastric distension,improve immune function,correct immune imbalance,reduce the expression levels of serum CA72-4 and sICAM-1,and do not increase the incidence of adverse reactions.
作者
慈书俊
梁惠
吴宁波
耿亚迪
CI Shujun;LIANG Hui;WU Ningbo;GENG Yadi(Lu’an Hospital of Traditional Chinese Medicine,Lu’an 237006,China)
出处
《陕西中医》
CAS
2024年第6期775-779,共5页
Shaanxi Journal of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(8180140119)
安徽省红十字会中医药传承创新发展研究项目(2021ZYYB08)。
关键词
胃癌
升阳除湿防风汤
多西他赛
顺铂
5-氟尿嘧啶
糖类抗原72-4
可溶性细胞间黏附分子-1
Gastric cancer
Shengyang Chushi Fangfeng decoction
Docetaxel
Cisplatin
5-fluorouracil
Carbohydrate antigen 72-4
Soluble intercellular adhesion molecule-1
